ArticleAmerican economic journal. Economic policy2022
Drug Diffusion Through Peer Networks: The Influence of Industry Payments.
Article in American economic journal. Economic policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? : A Systematic Review.Annals of internal medicine · 2021Pooled it
- New Medical Schools, Access to Physicians, and Health Outcomes: Evidence From Japan.Health economics · 2026Article
- Medical Device Industry Payments and Utilization of Corresponding Devices.JAMA network open · 2026Article
- How often do oncologists receive industry payments from competing companies?The oncologist · 2026Article
- Relationship between industry payments to physicians and prescription patterns for PCSK9is, ARNis and DOACs: A report from the NCDR PINNACLE registry.American heart journal · 2026Article
- Practice-Level Clustering of Industry Payments to Clinicians.Health services research · 2025Article
- Peer effects on appropriate antibiotic prescribing within a patient-sharing physician network in China.Communications medicine · 2025Article
- Spending Changes After Moving to Areas With Greater ACO Participation Among Nonattributed Medicare Beneficiaries.JAMA network open · 2025Article
- Hospital Allocation and Racial Disparities in Health Care.The review of economics and statistics · 2024Article
- Quantifying Industry Spending on Promotional Events Using Open Payments Data.JAMA health forum · 2024Article
- Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis.BMJ open · 2023Article
- Industry Payments to Physicians Are Kickbacks. How Should Stakeholders Respond?Journal of health politics, policy and law · 2022Article
- ORIGINS OF THE OPIOID CRISIS AND ITS ENDURING IMPACTS.The quarterly journal of economics · 2022Article
- Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines.The oncologist · 2021Article
- Drug company payments to General Practices in England: Cross-sectional and social network analysis.PloS one · 2021Article
- Physicians payment in the United States between 2014 and 2018: An analysis of the CMS Open Payments database.PloS one · 2021Article
- Network Analysis of Medical Claims Data Suggests Network-Based, Regional Targeting and Intervention Delivery Strategies to Increase Access to Office Based Opioid Treatment (OBOT) for Opioid Use Disorder (OUD).Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Pharmaceutical companies market to physicians through individual detailing accompanied by monetary or in-kind transfers. Large compensation payments to a small number of physicians account for most of this promotional spending. Studying US promotional payments and prescriptions for anticoagulant drugs, we investigate how peer influence broadens the payments' reach. Following a compensation payment, prescriptions for the marketed drug increase by both the paid physician and the paid physician's peers. Payments increase prescriptions to both recommended and contraindicated patients. Over three years, marketed anticoagulant prescriptions rose 23 percent due to payments, with peer spillovers contributing a quarter of the increase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.